Learn to Love Your Liver
The best way to stop liver cancer is to prevent it before it happens.
Blue Faery’s Love Your Liver program spreads awareness and educates high-risk, underserved populations to increase the prevention and early detection of liver disease and cancer. Given that minorities have higher rates of liver cancer, Love Your Liver seeks to improve health inequities and address social determinants of health.
Did you know that
1 in 3 American adults has liver disease
50% of Americans live with at least one of the leading risk factors for liver disease
Asian Americans and Pacific Islanders have the highest rates of liver cancer, followed by Hispanics/Latinos, American Indians/Alaska Natives, African Americans, and whites.
Love Your Liver for Blacks/African Americans
Blacks/African Americans are 1.5x more likely than White Americans to get liver cancer, and incidence rates are rising.
During Black History Month (February), Blue Faery has free educational programs for the Black community. These programs are culturally inclusive and are led by healthcare providers who reflect the community.
Love Your Liver for Asian Americans
Asian Americans are 2x more likely than White Americans to get chronic hepatitis B, the leading cause of liver cancer in the Asian American community.
During Asian American and Pacific Islander Heritage Month (May), Blue Faery has free educational programs for Asian Americans. Last year, we focused on Chinese Americans. These culturally inclusive programs are in their native language and are led by healthcare providers who reflect the community.
Love Your Liver for Hispanic Americans
Hispanics are 2.5x more likely than White Americans to develop liver cancer.
During Hispanic Heritage Month (September 15 – October 15), Blue Faery has free educational programs for the Hispanic community. These culturally inclusive programs are in their native language and are led by healthcare providers who reflect the community.
Contact us for corporate sponsorship opportunities!
Previous/current sponsors include AstraZeneca, Eisai, Exelixis, Genentech, and Merck.